Dose finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ARA-C in untreated elderly patients with acute myeloid leukaemia (AML).

被引：0
|
作者：
Sonneveld, P
Lowenberg, B
Vossebeld, P
Malkhandi, J
Covelli, A
Dekker, AW
Ossenkoppele, G
Milligan, D
Verhoef, G
Ferrant, A
Yin, J
Gratwohl, A
Kovacsovics, T
Burnett, A
机构：
[1] UNIV ROTTERDAM HOSP,ROTTERDAM,NETHERLANDS
[2] VRIJE UNIV AMSTERDAM,AZ,AMSTERDAM,NETHERLANDS
[3] UNIV UTRECHT,AZ,UTRECHT,NETHERLANDS
[4] BIRMINGHAM HEARTLANDS HOSP,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND
[5] MANCHESTER ROYAL INFIRM,MANCHESTER M13 9WL,LANCS,ENGLAND
[6] UZ GASTHUISBERG,LOUVAIN,BELGIUM
[7] UZ ST LUC,BRUSSELS,BELGIUM
[8] CHU VAUDOIS,KANTONSSPITAL BASEL,LAUSANNE,SWITZERLAND
[9] NOVARTIS PHARMA AG,BASEL,SWITZERLAND
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2517 / 2517
页数：1
相关论文
共 50 条
  • [21] Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia (AML) patients ≥ 60 years old:: Correlation of outcome with functional MDR (CALGB studies 9720 and 9760).
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2001, 98 (11) : 461A - 462A
  • [22] A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial
    Mussai, Francis J.
    Thomas, Ian
    Ariti, Cono
    Upton, Laura
    Sydenham, Mia
    Burnett, Alan K.
    Knapper, Steve
    Mehta, Priyanka
    McMullin, Mary Frances
    Copland, Mhairi
    Russell, Nigel H.
    Hills, Robert
    [J]. BLOOD, 2021, 138
  • [23] A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial
    Dennis, Mike
    Burnett, Alan
    Hills, Robert
    Thomas, Ian
    Ariti, Cono
    Severinsen, Marianne T.
    Hemmaway, Claire
    Greaves, Paul
    Clark, Richard E.
    Copland, Mhairi
    Russell, Nigel
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (02) : 298 - 308
  • [24] Feasibility study of temozolomide maintenance therapy in elderly patients with AML following induction therapy with high dose mitoxantrone and high dose ara-C
    Ponce, Doris
    Katragadda, Sreedhar
    Liu, Delong
    Rasul, Muhammad
    Ahmed, Nasir
    Ahmed, Tauseef
    Seiter, Karen
    [J]. BLOOD, 2007, 110 (11) : 164B - 164B
  • [25] Clofarabine combinations in acute myeloid leukemia (AML) salvage: A dose-finding phase I study of clofarabine plus idarubicin and clofarabine/idarubicin plus cytarabine (ara-C)
    Faderl, S
    Ferrajoli, A
    Wierda, W
    Ravandi, F
    Estrov, Z
    Verstovsek, S
    Thomas, DA
    Garcia-Manero, G
    Kwari, M
    Kantarjian, HM
    [J]. BLOOD, 2005, 106 (11) : 786A - 786A
  • [26] A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression
    Al-Kali, Aref
    Tibes, Raoul
    Atherton, Pamela
    Palmer, Jeanne
    Alkhateeb, Hassan B. B.
    Patnaik, Mrinal
    Begna, Kebede
    Gangat, Naseema
    Hashmi, Shahrukh
    He, Rong
    Litzow, Mark
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : 472 - 480
  • [27] Postremission therapy in adult acute myeloid leukemia (AML): A randomized comparison between high dose ara-C therapy and conventional consolidation therapy (JALSG AML 201 study).
    Miyawaki, Shuichi
    Ohtake, Shigeki
    Fujisawa, Shin
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Miyamura, Koichi
    Nishimura, Miki
    Miyazaki, Yasushi
    Nishii, Kazuhiro
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    [J]. BLOOD, 2006, 108 (11) : 567A - 567A
  • [28] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    [J]. BLOOD, 2001, 98 (11) : 211B - 211B
  • [29] Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (pts) with acute myeloid leukemia (AML) <60 years old:: Preliminary results of CALGB 9621.
    Kolitz, JE
    George, SL
    Hurd, D
    Hoke, E
    Dodge, RK
    Velez-Garcia, E
    Powell, BL
    Moore, J
    Caligiuri, MA
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 1999, 94 (10) : 384A - 384A
  • [30] A Randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients <60 years using P-Glycoprotein (Pgp) modulation with valspodar (PSC833):: Preliminary results of cancer and leukemia group B study 19808.
    Kolitz, JE
    George, SL
    Marcucci, G
    Vij, R
    Powell, BL
    Allen, SL
    De Angelo, DJ
    Shea, T
    Stock, W
    Hars, V
    Hoke, E
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2005, 106 (11) : 122A - 123A
12345